Abstract: Chronic hypertension in pregnancy is one of the most common medical diseases affecting pregnancy. It is associated with serious maternal and fetal complications, including superimposed pre-eclampsia, fetal growth restriction, premature delivery, placental abruption, and stillbirth. Baseline evaluation as early as possible is important to differentiate women with essential hypertension from those with severe hypertension, coexisting end-organ damage, and secondary causes of hypertension, as their risks of poor outcomes are increased. An optimal plan for maternal treatment and fetal surveillance can then be formulated. Coordination of care after delivery is important for long-term maternal health and future pregnancies.
Overview
The obesity epidemic in America has led to a growing number of women entering pregnancy with chronic hypertension. Because of the lack of care outside of pregnancy, for many women the diagnosis of chronic hypertension is made during or immediately after pregnancy. Proper evaluation is necessary to ascertain the degree of hypertension, presence of end-organ damage, and any secondary causes. Counseling can then be provided and a plan made for treatment and maternal and fetal surveillance. Vigilance for superimposed preeclampsia and timely delivery to prevent maternal and fetal morbidity and mortality are cornerstones of care. Postpartum follow-up is important to optimize future reproductive health and long-term maternal health.
Epidemiology of Chronic Hypertension and Pregnancy
The rate of hypertension in the United States continues to rise dramatically. The latest report from the Centers for Disease Control and Prevention 1 finds almost 1 in 3 adults have hypertension [defined as systolic blood pressure >140 mm Hg and diastolic blood pressure >90 mm Hg]. Hypertension is a major risk factor for heart disease and stroke, the first and third leading cause of death in this country. 2 For women of reproductive age (22 to 44 y), almost 8% are affected. 1 This number is expected to increase, as 64% of all women are overweight [body mass index (BMI) 25 to 29.9, 28.6%] or obese (BMI>30.0, 35.4%). 3 Since 1989, hypertension and diabetes have been the most common diseases affecting pregnancy. Recent data from all US births in 2009 demonstrate chronic hypertension has increased by 67% in the last 9 years, with an overall prevalence of chronic hypertension in pregnancy of 12.7 per 1000 live births and pregnancy-induced hypertension or gestational hypertension at 39. 4 per 1000 live births. This risk was significantly higher in older women and nonHispanic black women 4 ( Fig. 1) . Hypertension, whether pre-existing or pregnancy-induced can have significant adverse effects to the mother and fetus, including pre-eclampsia, fetal growth restriction, preterm birth, and stillbirth. Hypertensive disorders remain one of the leading causes of maternal death. 5 Given the high prevalence and significant morbidity and mortality in pregnancy, FIGURE 1 . Rate of hypertension in pregnancy by age and ethnicity. Rate per 1000 live births (total includes all births to US residents). Adapted from Martin et al. 4 
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Definitions of Hypertension in Pregnancy
Studies have been difficult to interpret because of a variety of definitions of hypertension complicating pregnancy. : Chronic hypertension is defined as hypertension that is present and observable before pregnancy or that is diagnosed before the 20th week of gestation. Hypertension is defined as a blood pressure Z140 mm Hg systolic or Z90 mm Hg diastolic. Hypertension that is diagnosed for the first time during pregnancy and that does not resolve postpartum is also classified as chronic hypertension.
Gestational hypertension is (1) transient hypertension of pregnancy if pre-eclampsia is not present at the time of delivery and blood pressure returns to normal by 12 weeks' postpartum (a retrospective diagnosis) or (2) chronic hypertension if the elevation persists.
Pre-eclampsia: The pregnancy-specific syndrome usually occurs after 20 weeks' gestation (or earlier in the case of trophoblastic diseases such as hydatidiform mole or hydrops). It is determined by increased blood pressure (gestational blood pressure elevation) accompanied by proteinuria, defined as the urinary excretion of Z0.3 g protein in a 24-hour specimen. Gestational blood pressure elevation is defined as a blood pressure >140 mm Hg systolic or >90 mm Hg diastolic in a woman who was normotensive before 20 weeks' gestation. In the absence of proteinuria the disease is highly suspected when increased blood pressure appears accompanied by the following symptoms: headache, blurred vision, and abdominal pain, or by abnormal laboratory test results, specifically low platelet counts and abnormal liver enzyme values.
Superimposed pre-eclampsia, in women with hypertension and no proteinuria early in pregnancy (<20 wk gestation), new-onset proteinuria, defined as the urinary excretion of Z0.3 g protein in a 24-hour specimen, is present. Or in women with hypertension and proteinuria before 20 weeks' gestation when any of the following are seen: sudden increase in proteinuria, sudden increase in blood pressure in a woman whose hypertension has previously been well controlled, thrombocytopenia (platelet count <100,000 cells/mm 3 ), increase in alanine aminotransferase or aspartate aminotransferase to abnormal levels.
Eclampsia is defined as the occurrence in a woman with pre-eclampsia of seizures that cannot be attributed to other causes.
The focus of this review will be on ambulatory management of chronic hypertension. This will not include patients with gestational hypertension and patients requiring hospitalization, such as those with severe hypertension, preeclampsia, and eclampsia.
Outcomes Related to Chronic Hypertension and Pregnancy
Chronic hypertension is associated with serious maternal and fetal complications, including superimposed pre-eclampsia, fetal growth restriction, premature delivery, placental abruption, and stillbirth.
These risks are increased in women with more severe hypertension. Fetal risks are increased even in the absence of superimposed pre-eclampsia. superimposed pre-eclampsia was 17.5% (range, 10% to 25%), placental abruption 0.9% (range, 0% to 1.5%), and delivery <37 weeks 23.9% (range, 12% to 34.3%) and small for gestational age (SGA) 11.4% (range, 8% to 15.5%). 9 In a more recent prospective study of 822 women, 22% had superimposed pre-eclampsia. Those with superimposed pre-eclampsia have a significantly higher rate of SGA (48% vs. 21%), preterm delivery (51% vs. 15%), and cesarean delivery (70% vs. 44%). Risk factors for developing superimposed pre-eclampsia included black race, increased BMI, smoking, chronic renal disease, and previous history of preeclampsia. 10 In a large study from the United States of 763 women with chronic hypertension, 25% developed superimposed pre-eclampsia. Baseline proteinuria was not associated with an increased risk of superimposed pre-eclampsia, but hypertension for longer than 4 years duration and a history of pre-eclampsia were both associated with a 1.6-fold increased risk. Baseline proteinuria, however, was associated with both a higher risk of preterm delivery ( <35 wk) and SGA.
11
Patients entering pregnancy with blood pressure in the severe range have significantly higher rates of superimposed pre-eclampsia, placental abruption, and perinatal morbidity and mortality. Maternal complications, such as pulmonary edema, hypertensive encephalopathy, retinopathy, cerebral hemorrhage, and acute renal failure are more likely with poorly controlled blood pressure and/or end-organ damage, such as renal insufficiency and left ventricular dysfunction. 9 In 1 study of 44 women with documented blood pressure >170/110 mm Hg in the first trimester, 52% developed superimposed pre-eclampsia. Maternal morbidity was significant with 1 case of placental abruption, pleural effusion, and postpartum hypertensive encephalopathy. Nineteen women had transient renal insufficiency and 1 case was persistent. There were 10 stillbirths and 1 neonatal death for a perinatal mortality rate of 25%. All of these deaths were in patients with superimposed pre-eclampsia. The preterm delivery rate ( <37 wk) was 70% and 43% were SGA. These outcomes occurred in women even with intensive monitoring and treatment. 12 
Management of Chronic Hypertension in Pregnancy: Initial Evaluation
Like any disease predating pregnancy, it would be ideal to have a diagnosis and optimal treatment instituted before conception. This would allow time for counseling and assurance that specific treatment choices are safe in pregnancy. However, this is unlikely to be the scenario. Approximately half of all women begin pregnancy without health insurance or access to primary care and end up using some version of Medicaid. Thus, for many women, pregnancy remains the gateway to medical care and the incentive to improve their health to optimize the outcomes for their baby.
In the absence of a diagnosis, the initial history and physical examination can direct further work-up. Most pregnant patients with chronic hypertension can be evaluated as an outpatient. However, initial evaluation of pregnant women presenting with severe range blood pressure should be done as an in-patient. This will allow stabilization of maternal blood pressure, with parenteral therapy if needed, and a timely work-up.
Depending on the gestational age, initial blood pressure may not reflect the baseline degree of hypertension. Blood pressure in pregnancy will fall by late first trimester, reach a nadir by 16 to 18 weeks, and not return to baseline, or higher, until early third trimester. History or prior records documenting blood pressures outside of pregnancy may be helpful.
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Again, because of lack of access to care when not pregnant, prior obstetrical records may be the only medical records for many women. Records of prior complications such as pre-eclampsia or hypertension necessitating delivery and complicated by perinatal morbidity/mortality are important. Every effort should be made to acquire prior medical records.
Excessively high blood pressure (>160/ 100 mm Hg) in a young woman (<30 y), paroxysmal or hypertensive crisis, and/or anxiety symptoms should prompt testing for pheochromocytoma. Although the 24-hour urine collection for catecholamines and metanephrines or plasma-free catecholamines are both acceptable screening tests, we favor the 24 urine collection of catecholamines given the lower specificity of plasma metanephrines levels (ie, 85% to 89%). Pheochromocytoma, a catecholamine producing tumor, is a rare tumor with an incidence of <0.2 per 10,000 pregnancies. These tumors, if undiagnosed, carry a risk of mortality for both mother and fetus as high as 58% and 56%, respectively. If diagnosed and treated, maternal and fetal mortality decrease considerably to 0% to 2% and 14% to 15%. Hence the importance of early diagnosis and treatment. 13 Cushing syndrome, primary aldosteronism/excessive mineralocorticoids, and renal artery stenosis are also treatable causes that warrant further evaluation if clinically suspected. Primary aldosteronism is rare during pregnancy; fewer than 30 cases have been reported. A normal pregnancy is characterized by elevated levels of plasma aldosterone and complicates the diagnosis of primary aldosteronism. For this reason we do not recommend screening these patients during pregnancy. We usually await the 6-week postpartum visit to check plasma aldosterone and plasma renin activity. 14 Imaging deemed necessary can be tailored to pregnancy if there is concern for adrenal tumors or renal artery stenosis. 7 Essential or primary hypertension of longer duration (>5 y) and maternal age greater than 40 years should be evaluated for end-organ damage such as cardiomegaly, ischemic heart disease, renal involvement, and retinopathy. Testing includes electrocardiography, echocardiography, ophthalmologic examination, and renal ultrasound.
Laboratory testing for all patients should include hemoglobin A1c to evaluate for diabetes and renal function testing, serum BUN/creatinine with 24-hour urine collection for creatinine and protein. At this time there is not adequate data to replace the 24-hour collection for proteinuria in pregnancy. The urinary spot protein:creatinine ratio appears to have reasonable accuracy for ruling out proteinuria of 300 mg/d or more in pregnant hypertensive women, but data are too limited at this time to advocate replacing the 24-hour urine. 15 In addition to the 24-hour renal protein collection, baseline pre-eclampsia labs-CBC, ALT/AST, LDH, and uric acid will be useful when attempting to diagnose superimposed pre-eclampsia later in the pregnancy. Although uric acid is not helpful in diagnosing pre-eclampsia in the setting of new-onset hypertension in pregnancy, it does seem to be helpful in diagnosing superimposed pre-eclampsia in pregnant women with chronic hypertension, a common diagnostic dilemma. The likelihood ratio for having superimposed preeclampsia with a uric acid of 5.5, 6.0, and 6.5 mg/dL was 2.5-, 2.3-, and 8.0-fold higher in 1 study. 16 Careful review of lifestyle and medications should be done. Nutritional advice with dietary consultation is encouraged. Angiotensin-converting enzyme (ACE) inhibitors should be discontinued as they are potentially deleterious in all trimesters of pregnancy. The ACE-inhibitor fetopathy of the second and third trimesters are well known and include oligohydramnios, fetal renal failure, growth restriction, pulmonary hypoplasia, hypocalvaria, hypotension, and stillbirth. 17 More recently, a retrospective study of Tennessee Medicaid data of linked records demonstrated teratogenicity with exposure to ACE inhibitors in the first trimester, with a significant increase primarily in cardiac and central nervous system defects. 17 Once the initial evaluation has been completed, a plan for the remainder of the pregnancy should be implemented. The goals in pregnancy are to optimize outcome for the mother and fetus by balancing the risks and benefits.
Treatment of Severe Chronic Hypertension
Treatment of the maternal blood pressure in the severe range, that is >160/110 mm Hg, is warranted to prevent worsening hypertension and central nervous system hemorrhage, cardiac decompensation, and renal damage/failure. Treating at systolic blood pressure of Z160 is indicated given that there seems to be an increased risk of maternal stroke at these levels. 18 Women found to have end-organ damage should be treated in pregnancy, even if blood pressure is in the mild range. This may benefit long-term maternal outcome by limiting further organ damage in pregnancy.
Treatment of Mild Chronic Hypertension
There is significantly controversy regarding treatment of mild range hypertension in the absence of end-organ involvement. Antihypertensive drugs are often used to lower blood pressure in the belief that they will prevent superimposed pre-eclampsia. A meta-analysis of 46 trials, involving 4282 women, could not demonstrate a benefit of antihypertensive drugs for mild to moderate hypertension during pregnancy. Treatment did not decrease the incidence of superimposed pre-eclampsia, preterm delivery, SGA, or perinatal mortality. However, there was a 50% reduction in the progression to severe hypertension. 19 An additional meta-analysis suggested a correlation of SGA with antihypertensive medications and a reduction in mean arterial pressure. This was not related to the type of antihypertensive medication or duration. For every decrease in mean arterial pressure by 10 mm Hg there was a fall in birth weight by 145 g. 20 Currently the CHIPS (Control of Hypertension in Pregnancy Study)trial, funded by the Institute of Health Research, is ongoing to answer the question of risk and benefits with treatment of mild chronic hypertension in pregnancy. The anticipated conclusion date is 2013.
Fortunately, the majority of pregnancies do well when the blood pressure remains in the mild range, superimposed pre-eclampsia does not develop, and there is no evidence of end-organ damage. Given the current limitations of the literature, management will be dictated by clinical judgment and informed consent. It is reasonable for patients entering pregnancy who are normotensive and not on any medications to be followed expectantly. Those who enter pregnancy well controlled on a medical therapy which is considered safe, can be continued (Table 1) . Those with blood pressure below 140/90 can also have medications discontinued and followed expectantly.
The b-blocker labetalol is considered a first line therapy by many practitioners. It is well tolerated and considered safe in pregnancy.
Labetalol is commonly preferred as some earlier reports found an association between atenolol and a higher risk of SGA. 21 Although dosed twice per day in nonpregnant individuals, 3 times per day is preferred in pregnancy as the functional half-life is shorter in pregnant women because of their increased hepatic and renal clearance. Of note, b-blockers have
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Methyldopa has been studied in pregnancy and is considered safe but the side effect profile, fatigue, and dry mouth, limits its use. Also, in a large meta-analysis of pregnant women with chronic hypertension, b-blockers were more effective than methyldopa in preventing the progression to severe hypertension. 19 For all of these reasons, many practitioners consider labetalol as first line treatment.
Nifedipine, slow release, has been found to be effective and safe in pregnancy. It also has the advantage of once daily dosing. 9 Antidiuretics have been discouraged because of concerns that a decrease in intravascular volume would be detrimental to uterine perfusion and therefore fetal growth. However, studies have not proven this. Five studies (1836 women) compared thiazide diuretics with either placebo or no intervention. No clear differences between the diuretic and control groups were demonstrated for the following outcomes: pre-eclampsia, perinatal death and preterm birth, and SGA. 23 If there is a clear maternal benefit from diuretics in controlling blood pressure, then this choice is reasonable. However, given the known decrease of intravascular volume, if pre-eclampsia and/or fetal growth restriction is diagnosed then diuretics should be discontinued. 9 And finally, as discussed previously, the ACE inhibitors should not be used as they are potentially deleterious to the fetus in all trimesters of pregnancy.
Antepartum Surveillance
Because of the risk of adverse outcomes, prenatal care and fetal surveillance are important. There is no definitive protocol for following these patients and expert opinion differs on antepartum testing strategies. 24 Patients with mild chronic hypertension and no end-organ involvement, should be followed carefully for any signs and symptoms of increasing blood pressure and superimposed pre-eclampsia and fetal growth restriction. Given that pre-eclampsia in these patients will likely develop in the second half of pregnancy, monthly evaluation is reasonable until the second half of pregnancy. The clinical course will dictate the frequency of visits in the third trimester.
Initial ultrasound examination to confirm dating is important to avoid iatrogenic preterm delivery if induction of labor is indicated later in the pregnancy. Anatomic survey at 18 to 20 weeks is then followed by serial ultrasound examinations every 4 weeks beginning at 28 weeks to document fetal growth. Antepartum testing with non-stress test or biophysical profile is commonly performed in these patients. Certainly weekly or biweekly testing with incorporation of amniotic fluid assessment is warranted in the setting of known fetal growth restriction.
Patients with severe hypertension and/ or significant end-organ damage will require much closer surveillance. After initial hospitalization, prenatal visits weekly or every other week to assess blood pressure control are needed, then weekly after 20 weeks. Antepartum surveillance and serial growth scans are started earlier in these patients as well.
Delivery Timing
Admission to the hospital and consideration of delivery should be done in any patient who develops uncontrolled hypertension, superimposed pre-eclampsia, fetal growth restriction, and/or nonreassuring fetal assessment.
For patients who remain uncomplicated with well-controlled blood pressure and reassuring maternal and fetal status, a large epidemiologic study demonstrated optimal delivery to be at 38 to 39 weeks to balance the risk of stillbirth and adverse neonatal outcome. 25 There is often concern by clinicians that they are weighing the risks of intervention with induction of labor and increasing the risk of cesarean delivery. Although induction of labor increases risk of cesarean as compared with spontaneous labor, it is less clear about the impact of induction of labor versus expectant management. 26 In the setting of chronic hypertension, expectant management carries with it the risk of stillbirth, developing intrauterine growth restriction, and of developing superimposed pre-eclampsia. In small randomized trials, induction of labor, even with an unfavorable cervix, was not associated with an increased risk of cesarean. 27 Thus, delivery by or at 39 weeks' gestation is often recommended. For pregnant patients who enter prenatal care late with mild hypertension, with or without proteinuria, management becomes very problematic. The diagnosis of chronic hypertension cannot be made until after delivery. Gestational hypertension or mild pre-eclampsia cannot be excluded. Pending a definitive diagnosis, the HYPITAT, a multicenter, open-label randomized controlled trial with induction of labor versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation, can be used to guide delivery timing. The study found patients that underwent labor induction beyond 37 weeks with gestational hypertension (diastolic blood pressure >95 mm Hg) or mild preeclampsia had significantly better maternal outcomes, primarily less progression to severe hypertension and HELLP syndrome. There was no difference in neonatal outcomes and a trend toward a lower rate of cesarean delivery in the induction group. 28 ACOG has recently endorsed a consensus panel for recommended timing of delivery in women with chronic hypertension (Table 2) . 24 
Prevention of Pre-eclampsia
Given the large numbers of women affected by pre-eclampsia and the considerable 30 has not demonstrated a reduction in the incidence of pre-eclampsia. Low-dose aspirin, as an antiplatelet agent, has been extensively studied. Overall, a large meta-analysis of 59 trials and 37,560 women did suggest that low-dose aspirin decreased the risk of pre-eclampsia, especially in women of high risk, such as those with chronic hypertension. 31 However, in the randomized controlled trials evaluating low-dose aspirin in high-risk groups (chronic hypertension, pregestational insulin-dependent diabetes, multifetal pregnancy, and previous pregnancy with preeclampsia) conducted by the NICHD's Maternal-Fetal Medicine Units Network did not demonstrate a reduction in preeclampsia. 32 One concern with that study was that patients were enrolled up to 20 weeks of gestation, and if the effect of aspirin is during placentation, the effect would not have been seen. The CLASP (Collaborative Low-dose Aspirin Study in Pregnancy), a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women, also did not find a significant reduction in the overall incidence of pre-eclampsia in the aspirin-treated group. However, in that study there was a reduction in the incidence of early pre-eclampsia (<32 wk) leading to preterm delivery. The rate of stillbirth, neonatal death, or fetal growth retardation occurring before 32 weeks was 5.3% in the aspirin group as compared with 10.6% in the placebo group. Therefore women in whom the use of low-dose aspirin may be justified are those at especially high risk of early-onset pre-eclampsia (ie, before about 32 wk). It is, however, not possible with precision to identify such women prospectively, but those with a previous history of early-onset pre-eclampsia might be considered. Because early-onset preeclampsia can begin at any time after 20 weeks' gestation, it seems appropriate for such women to start prophylaxis before this time, especially because later entry for therapeutic reasons in CLASP was, if anything, associated with increased perinatal mortality. 33 Thus we would recommend low-dose aspirin for all women with chronic hypertension. To achieve its potential benefit, we would recommend starting the lowdose aspirin before pregnancy, if possible, and as soon as possible during pregnancy.
Postpartum Management
Hypertensive disorders of pregnancy, especially superimposed pre-eclampsia and exacerbated hypertension, usually improve in the first week after delivery. Some cases may not improve after delivery and providers should be vigilant for any signs or symptoms of atypical preeclampsia or hypertensive crisis, which requires immediate in-patient observation and treatment. Hypertension originating in pregnancy and any associated complications, such as proteinuria, renal insufficiency, and other laboratory abnormalities should resolve by 6 weeks' postpartum. If still present the patient should be re-evaluated again in 6 weeks and if still persistent diagnosed as chronic. Patients with blood pressure medications discontinued after delivery also need careful follow-up to ascertain if the medications should be restarted. Breastfeeding is compatible with most antihypertensive medications ( Table 2) .
Counseling Regarding Future Pregnancies
Women who experience pregnancies affected with hypertensive disorders have an increased risk of recurrence in subsequent pregnancies. The estimate of this risk was recently defined using current definitions in a study from Finland of 896 women (Fig. 2) . 34 Depending on the diagnosis in the initial pregnancy, there is 58% to 94% recurrence risk of some type of hypertensive disorder in the second pregnancy. There is a higher risk of recurrence of hypertensive disorders in the next pregnancy if the diagnosis was made early in the first pregnancy (<34 wk), the patient is overweight and/or weight gain (defined as increase in BMI of >2 U, which is approximately a 6 kg increase in a women of average height) between the pregnancies. This will direct future counseling and management of pregnancies and provide impetus for a healthy lifestyle after pregnancy. 34 Thus, it is advisable to counsel women at the 6-week postpartum visit about these future risks, to begin discussing the plan for maintaining a healthier diet and exercise habits as they had during pregnancy, and helping them transition to a primary care provider who can further guide their interpregnancy health habits. Such patients should be advised to seek out a preconception consultation as well. To facilitate such consultations, the IUD is a great form of contraception as it requires a clinician visit for removal to become pregnant.
Conclusions
Given our inability to accurately determine which pregnant women with chronic hypertension will become complicated, all patients with this diagnosis should be considered high risk and followed closely. New research in this area will continue to define better treatment strategies aimed at improving maternal and fetal outcomes. Ongoing, coordinated care for these patients before and after pregnancy is important to optimize future reproductive health and long-term health for mother and baby. Chronic Hypertension in Pregnancy 753
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